14:22:23 EDT Wed 24 Apr 2024
Enter Symbol
or Name
USA
CA



Zentek Ltd
Symbol ZEN
Shares Issued 99,533,982
Close 2023-02-03 C$ 1.88
Market Cap C$ 187,123,886
Recent Sedar Documents

Zentek talks final ZenGuard phase 2 HVAC test results

2023-02-06 10:02 ET - News Release

Mr. Greg Fenton reports

ZENTEK ANNOUNCES FINAL RESULTS OF HVAC PHASE 2 TESTING

Further to its press releases dated April 11, 2022, and Dec. 15, 2022, Zentek Ltd. has received the final report for phase 2 testing of ZenGuard for use in heating, ventilation and air conditioning (HVAC) filtration from the National Research Council of Canada (NRC). ZenGuard-treated MERV (minimum efficiency reporting values) 8 filters achieved 34.56-per-cent filtration efficiency of the Phi6 virus, a surrogate for COVID-19, during a single air exchange. This compares with 7.24 per cent for uncoated MERV 8 filters, a 27.32-per-cent net improvement.

"We believe our patented technology platform, ZenGuard, is a disruptive technology for the HVAC industry, giving us the ability to help filter manufacturers significantly increase pathogen filtration efficiency of the most commonly used air filters. The ZenGuard technology is a simple and practical way to improve one of the biggest problems facing workspaces, planes, trains, buses and other indoor spaces: indoor air quality. Many building and transportation system owners and operators do not have the ability or desire to bear the financial costs of upgrading to higher-rated filters and HVAC systems. Additionally, avoiding the increased energy consumption and maintenance costs associated with higher-rated filters provides a strong environmental and economic incentive, further supporting the ZenGuard value proposition," said Greg Fenton, chief executive officer of Zentek. "For these reasons, we believe our patented ZenGuard technology has the potential to not only protect people's health by removing more pathogens from the air we breathe, but to do so in a way that reduces financial burden and environmental footprint."

Phase 2 testing

Testing was conducted in NRC's unique bioaerosol facility, a purpose-built 173.3-cubic-metre (6,120-cubic-foot) modular room intended to simulate a real-world classroom environment. The testing used Cystovirus Phi 6, a surrogate for enveloped viruses, including SARS-CoV-2, the causative agent of COVID-19. Importantly, the particle size distribution used for this study was representative of the size distribution expelled from the human respiratory tract where 85 per cent were in the E1 classification (0.3 to one micron) and 15 per cent were in the E2 category (one micron to three microns) and were at a concentration in line with ASTM E3273-21 -- Standard Practice to Assess Microbial Decontamination of Indoor Air using an Aerobiology Chamber. MERV 8 filters were not designed to capture particles this size, which is reflected in their low 7.24-per-cent filtration efficiency. In contrast, the ZenGuard technology had a meaningful effect on the viral filtration efficiency of the MERV 8 filter, increasing the efficiency by almost five times to 34.56 per cent in a single air exchange.

Next steps toward commercialization

Zentek has shared the phase 2 report with federal and provincial organizations for their review and analysis of the results. This is a step in the Innovation Solutions Canada commercialization pathway that could lead to potential agreements to sell ZenGuard-coated HVAC filters to governmental organizations.

Zentek is also continuing:

  • To optimize the company's product offerings by testing various configurations of HVAC filter materials coated with patented ZenGuard technology at LMS technologies in the United States;
  • To work with the Pest Management Regulatory Agency and the Environmental Protection Agency for regulatory approvals in Canada and the United States, respectively.

In addition, the company is reviewing a report from Intertek Group PLC that provides an overview of regulatory requirements in other geographies of interest to assess commercialization opportunities across the globe.

About Zentek Ltd.

Zentek is an intellectual property development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the health care industry and beyond.

Zentek's patented ZenGuard coating is shown to have 99-per-cent anti-microbial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC systems. Zentek's ZenGuard production facility is located in Guelph, Ont.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.